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There is no effective vaccine for Marburg virus (MBGV) or any other filovirus, nor enough pertinent information to expedite
rational vaccine development. To ascertain some of the minimal requirements for a MBGV vaccine, we determined whether
whole inactivated MBGV, or a baculovirus-expressed virion subunit, could be used to immunize guinea pigs against a lethal
infection. Baculovirus recombinants were made to express the MBGV glycoprotein (GP) either as a full-length, cell-associated
molecule or a slightly truncated (5.4%) product secreted into medium; the latter, for its far greater ease in manipulation,
was tested for its vaccine potential. Like MBGV GP, both the full-length and truncated GP expressed by baculovirus
recombinants were abundantly glycosylated with both N- and O-linked glycans; differences in glycosylation were detectable,
but these could not be shown to affect antigenicity with respect to available antibodies. The recombinant truncated glycopro-
tein elicited protection against lethal challenge with the MBGV isolate from which it was constructed and less effectively
against an antigenically disparate MBGV isolate. Killed (irradiated) MBGV antigen was protective, in a reciprocal fashion,
against both MBGV types. In a preliminary assessment of possible protective mechanisms, serum antibodies from immune
animals were shown to be sufficient for protecting naive guinea pigs from lethal MBGV infection.
INTRODUCTION have not yet been experimentally determined, functions
of the individual proteins have been proposed based
Marburg virus (MBGV), a member of the virus family upon their homology to better defined proteins found in
Filoviridae, causes acute hemorrhagic fever with high paramyxoviruses. The three structural proteins examined
mortality rates in both human and nonhuman primates. were NP, GP, and VP40. NP is a nucleocapsid protein
The first recognized infection of humans by MBGV oc- and most likely functions to encapsidate the viral RNA
curred in 1967 when simultaneous outbreaks of hemor- (Sanchez et al., 1992). VP40 is the most abundant compo-
rhagic fever occurred in Marburg and Frankfurt, Ger- nent of the virion, and most likely serves as a matrix
many, and in Belgrade, Yugoslavia (Martini and Siegert, protein, mediating interactions between the nucleopro-
1971). All cases were associated with laboratory workers tein complex and the lipid membrane (Feldmann et al.,
engaged in processing kidneys from African green mon- 1993; Elliott et al., 1985). GP is the viral glycoprotein,
keys for cell culture production (Smith et al., 1967). Two which trimerizes to form spikes, 7 nm long, on the surface
cases of hemorrhagic fever caused by a virus similar to of the virion (Feldmann et al., 1993, 1991; Geisbert and
the 1967 MBGV were identified in 1980 in Kenya (Smith Jahrling, 1995; Kiley et al., 1988). GP remains the only
et al., 1982). In 1987 MBGV was isolated from a fatal known viral protein exposed on the surface of the virion
case in Kenya, and was subsequently shown to differ and thus appeared to be an attractive target for neutraliz-
substantially from the original isolate (Johnson et al., ing antibodies. GP is abundantly glycosylated with over
1996). In all occurrences, infected individuals suffered
half its apparent molecular mass (Mr 170 KDa) attribut-severe illnesses with mortality rates more than 28%.
able to glycan (Feldmann et al., 1991, 1994; Becker et
The genome of MBGV consists of a single strand of
al., 1996). The MBGV genome, unlike that of Ebola virus,
RNA of minus polarity approximately 19 kb long. This
encodes the viral glycoprotein in a single open reading
RNA encodes 7 proteins, all of which are found in the
frame, resulting in the uncomplicated production of only
virion. Gene order is 3*-NP-VP35-VP40-GP-VP30-VP24-L-
a full-length transmembrane form of GP (Will et al., 1993;
5* and is similar to that of other members of the virus
Volchkov et al., 1995; Sanchez et al., 1996).
order Mononegavirales (which also include Paramyxovi-
It is unsettling, with a lethal pathogen like MBGV, toridae and Rhabdoviridae) (Feldmann et al., 1992). Al-
have no efficacious vaccine or therapy, and to possessthough the functions of most of the MBG viral proteins
only minimal and somewhat discouraging data per-
taining to successful vaccination in animals (i.e., Skrip-
chenko et al., 1994 and Ignat’ev et al., 1995 reported1 To whom correspondence and reprint requests should be addressed.
Fax: (301) 619-2290. E-mail: alan_schmaljohn@detrick.army.mil. survival after MBGV challenge of only 50% of nonhuman
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primates and 40–60% of guinea pigs previously immu- al., 1993; Sanchez et al., 1989). The GP gene from pGem-
GP was subcloned into pBluescript-KS(/) using classicalnized with formalin-inactivated MBGV antigen). The reas-
suring knowledge that outbreaks of human disease have molecular biology techniques (Sambrook et al., 1989).
The full-length GP gene was excised from the resultingbeen uncommon and self-limited is counterbalanced by
an almost complete ignorance of the virus’ natural host, clone (pKS-GP) with EagI and EcoRI, and this fragment
ligated into the NotI and EcoRI sites of the AcNPV trans-the factors that restrict the virus to its current ecological
niche, and the potential for wider spread. Currently, a fer vector pVL1392. The resulting clone was designated
pVL1392-GP.vaccine for MBGV might be realistically appropriate only
for health care workers in areas where the threat of A deletion mutant of GP, which resulted in a 37 amino
acid carboxyl-terminal-truncated protein missing theMBGV disease exists, international teams most likely to
respond to active outbreaks, and a small population of transmembrane domain of GP, was constructed using
PCR. This gene and its product were designatedlaboratory workers. Data reported herein suggest there
are no extraordinary barriers to MBGV vaccine develop- GPDTM. Forward (5*-CAGAAGCTTCCCTAACATGAA-
GACC-3*) and reverse (5*-CTGAAGCTTATTTACCAC-ment, and that the single viral glycoprotein may be a
sufficient protective antigen. CCAGAC-3*) primers for GPDTM contained HindIII
cleavage sites (underlined). All PCR reactions were per-
formed with 1 ng of pGem-GP as template DNA, 1 mgMATERIALS AND METHODS
each of forward and reverse primer, and the thermosta-
Cell cultures and viruses ble polymerase Pfu (Stratagene Cloning Systems, La
Jolla, CA). The reaction conditions used were: 15 cyclesSf 9 cells (Invitrogen, San Diego, CA), derived from
of 947C for 1 min, 557C for 1 min, and 727C for 1 min,Spodoptera frugiperda ovary, were maintained in Sf900
followed by a final extension step at 727C for 5 min. TheII serum-free medium (Gibco BRL, Gaithersburg, MD) at
PCR product was ligated into the SmaI site of pBlue-277C, as were High Five cells (Invitrogen, San Diego,
script-KS(/), and positive clones were identified. TheCA), derived from Trichoplusia ni egg cell homogenates.
GPDTM gene was subcloned into the HindIII site ofAutographa californica nuclear polyhedrosis virus
pBluebac III.(AcNPV) and recombinant viruses were cultured and as-
sayed in Sf 9 cells according to previously published
Production of recombinant baculovirusesmethods (O’Reilly et al., 1992). Vero E6 cells (Vero C1008,
ATCC CRL 1586) were grown in minimal essential me- Recombinant baculoviruses were generated by co-
dium with Earle’s salts supplemented with 10% fetal bo- transfection of an AcNPV transfer vector containing a
vine serum and gentamicin (50 mg/ml). MBGV (strain Mu- MBGV gene insert and linear wild-type baculovirus DNA
soke) was isolated from a human case in 1980 in Kenya into the Sf9 cell line according to standard methods
(Smith et al., 1982). Because this virus is virulent for (O’Reilly et al., 1992). Briefly, progeny in the transfection
nonhuman primates but not rodents, it was adapted for supernatant were screened by plaque assay for the oc-
guinea pig lethality by eight consecutive passages in clusion-negative phenotype. The clones of recombinant
strain-13 guinea pigs (inoculating subcutaneously, har- virus identified as occlusion-negative were plaque puri-
vesting spleen). A virulent plaque-purified derivative was fied three times in succession. After purification, clones
obtained from the guinea pig passage eight material, were amplified by growth in Sf9 cells, cultured in serum-
thrice plaqued in Vero E6 cells. MBGV (strain Ravn) was free medium, expanding from a 24-well plate (1 1 105
isolated from a fatal human case in 1987 in Kenya (John- cells/well), to a T25 (3 1 106 cells/flask), followed by
son et al., 1996). This virus was similarly adapted for growth in 100 ml suspension of Sf9 cells (1.51 106 cells/
guinea pig lethality but required only two passages, and ml). The titer of the final stock of recombinant baculovirus
a three-time plaque-purified virulent virus was obtained was determined by plaque assay on Sf9 cells.
from the guinea pig passage 2 material. Plaques picked
from MBGV (strain Musoke), guinea pig passage 6, were Expression of recombinant protein in Sf9 cells
variably lethal or in some cases completely nonlethal for
Sf9 cells grown in a 6-well plate at a density of 1 1strain-13 guinea pigs, and one of the nonlethal plaque-
106 cells/ml were infected at a multiplicity of infectionpicked derivatives was chosen as an immunizing virus
(m.o.i.) of 1 PFU per cell. Cells were metabolically labeledfor preparation of immune serum.
sequentially every 24 h, starting at 24 h postinfection and
continuing until 72 h postinfection. For each time point,Construction of the AcNPV recombinant transfer
the infected cells were starved for 30 min in Sf900 IIvectors and recombination with AcNPV
serum-free medium without cysteine or methionine, fol-
lowed by labeling for 4 h in the same medium supple-Marburg gene clone pGem-GP was generously pro-
vided by Heinz Feldmann and Anthony Sanchez (Centers mented with 100 mCi/ml each of [35S]methionine and
[35S]cysteine. After 4 h, the supernatant was removed,for Disease Control and Prevention, Atlanta, GA) (Will et
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mixed with an equal volume of 21 extraction buffer (100 acetylgalactosamine cores of O-glycans; Datura stramo-
nium agglutinin (DSA), which binds galactose b(1-4)glu-mM Tris–Cl, pH 8.0, 200 mM NaCl, 2% NP-40, 2% Trasy-
lol, 200 mg/ml PMSF), and stored at 0707C. The cells cosamine in complex or hybrid type glycans; Galantus
nivalis agglutinin (GNA), which recognizes terminal man-were lysed in 500 ml of 11 extraction buffer on ice for 5
min, and nuclei were pelleted at 800 g for 5 min. The nose linked a(1-3), a(1-6), or a(1-2) to mannose found in
N-glycans; Maackia amurensis agglutinin (MAA), whichresulting cytoplasmic extract was stored at 0707C. For
scale-up of protein production, 50- or 100-ml suspension reacts specifically with a(2-3)-linked sialic acids; and
Sambucus nigra agglutinin (SNA), which reacts with a(2-cultures of insect cells were infected with recombinant
baculovirus at an m.o.i. of 1, and cells or medium were 6)-linked sialic acids.
harvested at the peak time of expression.
Growth and concentration of MBGV
Immunoprecipitation of recombinant MBGV proteins MBGV strain Musoke or strain Ravn were grown in
Vero E6 cells and, in some instances, further concen-Expression of recombinant protein was analyzed by
trated. Briefly, Vero E6 cells seeded into roller bottlesimmunoprecipitation (Schmaljohn et al., 1987, 1983).
and grown to confluency were infected with MBGV at aBriefly, convalescent guinea pig anti-MBGV polyclonal
low m.o.i. (0.05). On day four postinfection, the mediumserum was adsorbed to protein A Tris–acryl beads
in each roller bottle was replaced with 40 ml of EMEM(Pierce Immunotechnology, Rockford, IL) in a ratio of 15
supplemented with 10% FBS. Supernatant from roller bot-ml serum:100 ml 50% bead slurry at 47C for 1 h with
tles was harvested at the time peak cytopathic effectscontinuous rocking. Unbound antibody was removed by
were observed, typically 6–7 days postinfection. The me-washing the beads once in 0.5 ml Zw wash buffer (10
dium was clarified (15 min, 1500 g) and virus concen-mM Tris–Cl, pH 8.0, 500 mM NaCl, 1 mM EDTA, 0.4%
trated by polyethylene glycol precipitation (7.5% w/w,Zwittergent 3-14, 1% Trasylol, 100 mg/ml PMSF). One hun-
NaCl adjusted to 0.5 M) at 47C for 4 h. After centrifugationdred microliters of a 50% slurry of antibody-coated beads
at 10,000 g for 30 min, pellets were resuspended in TNEin Zw wash buffer was mixed with 100 ml labeled sample
(10 mM Tris–Cl, pH 7.4, 150 mM NaCl, and 1 mM EDTA)and the suspension incubated overnight at 47C on a
overnight at 47C. One-milliliter aliquots of the resus-rocker. Beads were washed three times in Zw wash
pended PEG pellet were layered atop 20–60% sucrosebuffer at 47C and the final pellet was resuspended in 50
(prepared in TNE) gradients and the gradients were cen-ml of disruption buffer (50 mM Tris–Cl, pH 6.8, 4% SDS,
trifuged at 38,000 rpm in an SW41 rotor for 4 h. The visible4% b-mercaptoethanol, 10% glycerol, 1 mg/ml bromophe-
virus band was collected. Samples were inactivated bynol blue) and heated in a boiling water bath for 5 min.
irradiation (6MR, 60Co source) and tested for absence ofBeads were pelleted and 25 ml of the resulting sample
infectivity in cell culture before use.was electrophoresed on a 12.5% SDS–polyacrylamide:
DATD gel.
Metabolic labeling of MBGV
Lectin blots for the analysis of the carbohydrate Vero E6 cells were infected at a high m.o.i. (5–10).
content of recombinant expressed MBGV GP After 28 h, growth medium was removed, and infected
and GPDTM cells were starved for 30 min in MEM lacking cysteine
and methionine. Cells were refed with MEM without cys-The carbohydrate content of recombinant expressed
teine or methionine, supplemented with 2% FBS, 100 mCi/MBGV GP genes and GP from purified MBGV was com-
ml [35S]methionine, and 100 mCi/ml [35S]cysteine. Cellspared using the DIG (digoxigenin) Glycan Differentiation
were labeled for 18–20 h. Medium was removed fromkit (Boehringer Mannheim, Indianapolis, IN), following
the cells, clarified (1500 g, 15 min), and virus was pelletedthe manufacturer’s instructions. Briefly, 10 ml of unlabeled
by centrifugation (2 h, SW28 rotor at 25,000 rpm).Sf 9 lysate or supernatant was electrophoresed on a
12.5% SDS–polyacrylamide gel and the proteins in the
Monoclonal antibodies directed against MBGV strain
gel were transferred to Immobilon-P PVDF membrane
Musoke
(Millipore, Bedford, MA). Membranes were blocked over-
night at 47C then were incubated with lectin-DIG at room Ten female Balb/C mice were immunized twice subcu-
taneously at one site, dorsally, near the base of the tail,temperature for 1 h, followed by washing three times.
Anti-DIG-alkaline phosphatase was incubated with each on days 0 and 66, with irradiated MBGV (strain Musoke)
(20–40 mg/mouse) emulsified in Freund’s incomplete ad-membrane for 1 h at room temperature. The membranes
were washed three times and developed with a BCIP/ juvant. Sera obtained 12 days after the second immuniza-
tion were assayed for MBGV-specific antibody by ELISA,NBT stain. Reactions were stopped by rinsing with 10
mM EDTA followed by H2O. The following lectins were Western blot, and radioimmunoprecipitation against puri-
fied virion. A third immunization, administered intrave-used: Arachis hypogaea (peanut) agglutinin (PNA), which
specifically binds the unsubstituted galactose b(1-3)N- nously in HBSS on day 112, was given to three mice
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whose sera had reacted particularly well with MBGV GP.
Three days (two mice, fusions I and II) or 4 days (one
mouse, fusion III) after the third immunization, spleens
were taken from these three mice. Cells were fused with
SP2/0 myeloma cells according to standard methods for
fusion and cell husbandry; hybridomas from wells with
ELISA-positive supernatants were subcloned twice by
limiting dilution (Early and Osterling, 1985).
ELISA using GPDTM or purified MBGV as antigen
Flexible PVC ELISA plates (Dynatech Laboratories,
Chantilly, VA) were coated with 50 ml of antigen/well
diluted in PBS and held overnight at 47C. The antigen
used to coat the plates was a 1:500 dilution of irradiated
MBGV (1 mg/ml total protein  100 mg/ml GP) or 1:50
of GPDTM (10 – 20 mg/ml). To block nonspecific bind-
ing, 200 ml of 5% nonfat dry milk in PBS containing 0.02%
Tween 20 (PBSTM) was added to each well and plates FIG. 1. Immunoprecipitation of MBG proteins expressed in Sf9 cells
with convalescent guinea pig polyclonal anti-MBGV serum. Sf9 cellswere incubated at room temperature for 1 h. Plates were
were infected with recombinant baculoviruses that expressed the trun-washed five times with 200 ml/well PBS containing 0.02%
cated secreted Marburg glycoprotein (GPDTM), Marburg glycoproteinTween 20 (PBST). Primary antibodies were diluted in
(Baculo. GP), or wild-type baculovirus (wt Baculo.) at an m.o.i. of 1. At
PBSTM containing 1% heat-inactivated fetal calf serum, 48 h postinfection, both cell lysate (C) and supernatant (S) were col-
and 50 ml of diluted antibody was added to each well. lected. The samples were immunoprecipitated and analyzed by SDS–
PAGE. The positions of 35S-labeled MBGV (strain Musoke) structuralThe test sera (primary antibody) was diluted down the
proteins from virus grown in Vero E6 cells are shown.plate in duplicate by half-log (3.16-fold) dilutions. Plates
were incubated for 1 h at room temperature and washed
five times with PBST. Secondary antibody was either
with 100–1000 PFU guinea pig-adapted MBGV. Animals
horseradish peroxidase (HPO)-labeled goat-anti-mouse
were examined daily for signs of illness. On day 7 postin-
(IgM, IgG, IgA) or HPO-goat-anti-guinea pig (IgG H / L)
fection animals were bled for determination of plasma
(Cappel), diluted to 1:2000 in PBSTM containing 1% heat-
viremia titers. On day 14 postinfection, any surviving ani-
inactivated fetal calf serum. Diluted secondary antibody
mals were bled and viremias assessed. Animals were
(100 ml) was added to the appropriate wells and the
followed until at least 28 days after infection, anesthe-
plates were incubated for 1 h at room temperature. Plates
tized, and exsanguinated. Viremias were determined, by
were washed five times with PBST and 100 ml of 2,2*-
direct plaque assay on Vero E6 cells (Moe et al., 1981),
Azinobis-[3-ethylbenzothizoline-6-sulfonic acid] diam-
from heparinized plasma collected on days 7 and 14
monium salt (ABTS) substrate was added to each well.
postinfection.
After a 30-min incubation at room temperature, the opti-
cal density of each well at 405 nm was determined. End-
Passive protection in naive guinea pigs
points were calculated using a four-parameter curve fit
(SOFTmax software, Molecular Devices Corp.) of back- Sera from immune strain 13 guinea pigs were adminis-
ground subtracted mean OD versus dilution, followed by tered intraperitoneally to naive Strain 13 guinea pigs 2 h
extrapolation of the dilution at which the OD was 0.20. before subcutaneous inoculation with either MBGV
(strain Musoke) or MBGV (strain Ravn) (1000 PFU guinea
Immunization protocol for guinea pigs pig adapted MBGV). Animals were examined every day
for signs of illness. A day 10 postinfection bleed wasInbred strain 13 or outbred Hartley guinea pigs were
obtained for determination of plasma viremia.immunized subcutaneously with antigen prepared in RIBI
MPL / TDM / CWS (Monophosphoryl Lipid / Synthetic
RESULTSTehalose Dicorynomycolate / Cell Wall Skeletion) emul-
sion (RIBI ImmunoChem Research Inc.) with a total vol- Analysis of protein products expressed from
ume of0.5 ml administered at two dorsal sites. Animals recombinant baculoviruses
were anesthetized, bled, and subsequently boosted with
another dose of antigen approximately 28 days after pri- Protein products produced from the recombinant bacu-
loviruses were analyzed and compared with proteinsmary inoculation. A second bleed and boost was per-
formed approximately 28 days after the first. The animals from MBGV (Fig. 1). Samples were immunoprecipitated
from either cell lysates or supernatant. GPDTM was thewere bled 14 days later and challenged subcutaneously
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TABLE 1 the positive, albeit weak, binding to GNA reported by
Feldmann et al. (1991). Surprisingly, the recombinantReactivities of Virion-Associated and Recombinant MBGV
GPDTM in supernatant was found only to bind PNA.Glycoprotein wth Lectins
In contrast to the GPDTM protein, the GP protein re-
Lectin acted strongly with GNA and PNA, and weakly with MAA
and DSA. The strong reaction with GNA indicates that
GNA DSA PNA MAA SNA
a significant amount of the glycan associated with the
recombinant membrane-bound GP is of the high man-Virion GP 0 /// /// 0 0
Sf9 GP /// / /// / 0 nose type and thus represents unprocessed N-glycan.
Sf9 GPDTM 0 0 /// 0 0 However, the weak reaction observed with DSA indicates
that some complex N-linked glycans are present on the
Note. /// Indicates a very strong reactivity. / Indicates a weak
molecule and thus a minority of the glycans are pro-signal.
cessed. Reactivity with PNA indicates that at least some
of the O-linked glycosylation sites are being utilized in
the insect cells. Finally, weak reaction with MAA mayonly recombinant protein readily demonstrable in cell-
indicate the presence of sialic acid residues in the re-free supernates. Both the GP and GPDTM produced in
combinant GP protein that are not found in the virion-Sf 9 cells migrated faster than authentic GP from MBGV
associated protein.grown in Vero E6 cells, but considerably more slowly
than their core molecular masses predicted from amino
Reactivity of recombinant GPDTM antigen withacid sequence (74.4 kDa for GP and 70.1 kDa for
antibodies specific for MBGV GPGPDTM). This observation, which suggests substantial
but incomplete glycosylation of GP in Sf9 cells compared The reactivity of a subset of monoclonal antibodies
to GP in Vero cells, is consistent with data reported pre- (Mabs) with recombinant GPDTM protein from Tri-
viously (Becker et al., 1996). Somewhat unexpectedly, choplusia ni cells, MBGV (strain Musoke), and MBGV
GPDTM from Sf 9 supernatant appeared more heteroge- (strain Ravn) was examined by ELISA (Table 2). Of the
neous in size than either GPDTM or GP in cells, possibly GP-specific Mabs examined, all reacted equally well with
indicating differential glycosylation. In addition, the MBGV (strain Musoke) antigen and recombinant GPDTM
GPDTM in supernatant had an apparent maximum mo- except Mab III-5B8, which demonstrated a titer about
lecular mass greater than that of full-length GP and the 100-fold lower to GPDTM antigen. Only two of the MBGV
GPDTM found in cells, an observation which was repro- GP-specific Mabs reacted with MBGV (strain Ravn) GP
ducible in multiple experiments (data not shown). A sec- (II-7G8 and III-3H10). Mabs specific for MBGV proteins
ond major product at 86 kDa was immunoprecipitated other than GP did not react with recombinant GPDTM.
from Sf 9 cells expressing the recombinant GP. This prod- The NP- and VP-40-specific Mabs crossreacted well be-
uct may represent either a stable breakdown product of tween MBGV strains Musoke and Ravn, while the two
the full-length GP or incompletely glycosylated protein. VP-30-specific Mabs did not. Experiments (not shown)
Considering that GP of MBGV is modified with both O- involving reciprocal competitive inhibition and epitope
and N-linked oligosaccharides that contribute nearly half mapping have demonstrated the GP-specific Mabs in
of the molecular mass of fully processed GP, the differ- Table 2 to react with at least six distinct epitopes,
ences observed in the apparent molecular masses of whereas the two VP-30 Mabs are thus far indistinguish-
the glycoproteins may be explained by the differential able from one another.
glycosylation in insect cells (Sf9) when compared to The GPDTM in serum-free supernatants was demon-
mammalian cells (Vero E6) (Becker et al., 1996). strated to be a useful antigen for detection of anti-GP
response in guinea pig serum (Fig. 2). A titration of serum
Carbohydrate content of baculovirus produced MBGV from convalescent guinea pigs against both purified
proteins compared with proteins found in intact MBGV and GPDTM demonstrated that a substantial por-
virions tion of the antibody response in the convalescent ani-
mals was directed against GP. The interpolated end-
The extensive N- and O-linked glycosylation normally
points in log10 of convalescent serum versus GPDTMfound with MBGV GP was examined using various lectins
and virion were determined to be 4.02 and 4.67, respec-
to determine the extent of glycan processing in the re-
tively.
combinant GP proteins compared to the virion protein
(Table 1). It was clear that the three versions of GP dif- Immunization of strain 13 guinea pigs with an
fered in glycan content. The virion-associated GP bound inactivated MBGV vaccine and Sf9-produced GPDTM
both PNA and DSA as reported previously, indicating the
presence of complex or hybrid glycans, as well as O- Antigens used in the first experiment (four groups of
10 animals each) were: cell-free Sf9 supernatants con-linked glycans. However, we were not able to reproduce
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TABLE 2 animal that survived demonstrated a 2.5 log10 viremia on
day 7 postinfection). It was evident that all animals wereReactivity of Monoclonal Antibodies with MBGV
exposed to virus, and that some viral replication hadand Recombinant Antigens
probably occurred, since a boost in serum antibody titer
Log10titer of MAba was observed in all surviving animals after challenge.
Animals in group 2 that were challenged with MBGV
MBGV- MBGV-
(strain Ravn) all succumbed to infection with a mean dayAntibody Musoke Ravn GPDTM Specificity Isotype
of death of 9 days. All animals demonstrated a high se-
III-3H5 5.94 3.0 6.09 GP M rum viremia on day 7 postinfection, with values no differ-
II-9G4 6.26 2.0 6.38 GP G1 ent than those of the control group 4 (P  0.94).
III-4B11 6.13 2.0 6.29 GP G1 Those animals in groups 5 and 6, which were immu-
III-5E2 5.54 2.0 5.60 GP G1
nized with MBGV (strain Musoke), and those in groupsIII-5B8 5.68 2.0 3.76 GP G1
7 and 8, which were immunized with MBGV (strain Ravn),II-7C11 6.41 2.0 6.37 GP G1
III-4C9 5.28 2.0 5.24 GP G1 all had high serum ELISA titers (105) to both strains of
II-10D10 5.53 2.0 5.60 GP G1 MBGV prior to challenge. In addition, all animals chal-
II-7E9 5.91 2.0 6.33 GP M lenged in these groups survived without regard to chal-
II-7G8 5.38 5.47 5.42 GP G3
lenge virus. No viremia was detected in any of theseII-9F8 6.12 2.0 5.39 GP G3
animals. No boost in ELISA titer was observed in survi-II-10D9 5.82 2.0 5.77 GP ND
III-2C12 5.57 2.0 5.92 GP G1 vors, suggesting the possibility of sterile immunity.
II-7E10 6.5 2.0 6.46 GP M
III-2C10 5.67 2.0 5.80 GP G1 Comparison of protection in strain 13 and Hartley
III-5D7 5.24 2.0 5.30 GP G1
guinea pigs using recombinant antigens from twoIII-3H10 6.38 3.93 6.18 GP M
different insect cell linesIII-10D5 6.50 6.47 2.0 NP M
III-5F8 6.5 6.5 2.0 NP M
Six groups of eight animals were immunized as de-III-5F7 6.5 6.5 2.0 NP M
III-10D6 6.41 6.49 2.0 NP M scribed under Materials and Methods and Table 4. Three
III-5F11 5.30 2.0 2.0 VP30 G1 of those groups were made up of strain 13 guinea pigs
III-5F12 5.26 2.0 2.0 VP30 G1 and three were Hartley guinea pigs. Cell-free Sf9 super-
III-1H11 4.47 4.75 2.0 VP40 G1
natants containing GPDTM or cell-free Trichoplusia ni
supernatants containing GPDTM were each adminis-a Mab-containing ascitic fluids were precipitated with 50% saturated
ammonium sulfate, dialyzed, electrophoresed, stained, analyzed by tered to one group of Hartley guinea pigs and one group
densitometry, and adjusted to 2 mg/ml Mab content based on this of strain 13 guinea pigs. The dose for each of these
estimate. Endpoint was the extrapolated dilution at which the OD405 antigens was determined to be 5 and 25 mg/injection,
was 0.2. ND, not determined.
respectively. As controls, adjuvant in PBS was adminis-
tered to the remaining group of Hartley guinea pigs, while
taining GPDTM (0.5 mg/dose); cell-free, wild-type bacu-
lovirus-infected supernatants; gradient-purified MBGV
(strain Musoke) (100 mg/dose); and gradient-purified
MBGV (strain Ravn) (100 mg/dose). To evaluate protective
immunity, each group was divided and half the animals
challenged with guinea pig adapted MBGV (strain Mu-
soke) and half with guinea pig adapted MBGV (strain
Ravn). Results are shown in Table 3. ELISA titers were
determined for each animal against both MBGV (strain
Musoke) and MBGV (strain Ravn) antigens, using serum
collected 2 days before challenge and 28 days after chal-
lenge. In groups 1 and 2 (GPDTM), ELISA titers to MBGV
(strain Musoke) were about fivefold higher than to Ravn
antigen before challenge. Upon challenge with MBG-
Mus, 4/5 animals in group 1 survived, with 1 animal suc-
cumbing on day 12, not significantly later than the mean
day of death of control animals in group 3. No viremias
were detected on day 7 in any of the survivors of group
FIG. 2. Comparison of GP-specific versus anti-MBGV antibody re-
1, whereas the animal that died had a detectable but low sponses in convalescent guinea pig serum. Graph of OD versus dilution
day 7 viremia. This contrasts with control animals in of convalescent guinea pig serum assayed on either purified MBGV
(strain Musoke) (n) or GPDTM antigen (h).group 3 which all had high serum viremias (even the
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TABLE 3
Results of MBGV Challenge of Strain 13 Guinea Pigs Vaccinated with Either Killed MBGV or Sf9-Produced GPDTM
Log10 GMT ELISA Titer { SD Log10
PFU/ml
Musoke antigen Ravn antigen viremia
Challenge GMT { SD
Group Antigen Day 0 Day 02 Day 28 Day 02 Day 28 Day 7 MDD { SD S/T
1 GPDTM MBGV strain 4.2 { 0.3 5.6 { 0.3 3.5 { 0.5 4.5 { 0.1 2.7† 12† 4/5
Musoke
2 GPDTM MBGV strain 4.0 { 1.4 — 3.3 { 1.1 — 4.8 { 0.8 9 { 1.6 0/5
Ravn
3 Control baculovirus MBGV strain 1.5 — 1.5 — 4.0 { 1.0 11 { 0.8 1/5
Musoke
4 Control baculovirus MBGV strain 1.5 — 1.5 — 4.7 { 0.5 11 { 0.0 0/5
Ravn
5 Musoke virion MBGV strain 5.6 { 0.3 5.4 { 0.3 5.1 { 0.4 4.7 { 0.4 1.7 — 5/5
Musoke
6 Musoke virion MBGV strain 5.6 { 0.2 5.5 { 0.1 5.3 { 0.3 5.0 { 0.2 1.7 — 5/5
Ravn
7 Ravn virion MBGV strain 5.0 { 0.6 5.2 { 0.6 5.3 { 0.6 5.1 { 0.4 1.7 — 5/5
Musoke
8 Ravn virion MBGV strain 5.4 { 0.2 5.8 { 0.5 5.6 { 0.3 5.4 { 0.2 1.7 — 5/5
Ravn
Note. MDD, Mean day of death; S/T, survivors/total; GMT, geometric mean titer. †Represents data from the animal(s) that died. All geometric
mean ELISA titers were determined using sera from surviving animals.
PBS was administered to the remaining group of Strain and challenged with MBGV (strain Musoke) all survived
challenge (groups 15 and 17). None of the animals in13 guinea pigs. Before the time of challenge (day 0), the
animals were divided into 12 groups, numbered 9–20, either of the groups had a detectable viremia on day 7,
and no rise in antibody titer was observed after challengeand challenged with either guinea pig-adapted, plaque-
picked MBGV (strain Musoke), or guinea pig-adapted, in either group. In general, animals that were immunized
with GPDTM and infected with MBGV (strain Ravn) faredplaque-picked MBGV (strain Ravn). ELISA titers were de-
termined for each animal against both MBGV (strain Mu- worse (50% survival) than those challenged with MBGV
(strain Musoke) (90% survival).soke) and MBGV (strain Ravn) antigens using serum col-
lected 3 days prior to challenge and 33 days after chal-
lenge. No significant difference in response to antigen Passive transfer of serum from immune animals into
produced in Sf9 versus that produced in Trichoplusia ni naive animals
was observed in either the Hartley or strain 13 guinea
pigs (P  0.43 and P  0.74, respectively). In addition, To determine whether humoral immunity could be suf-
ficient to protect guinea pigs from lethal MBGV chal-the antibody responses as measured by ELISA were in-
distinguishable between strain 13 and Hartley guinea lenge, a transfer of serum obtained from immune animals
into naive animals, followed by challenge, was per-pigs.
Again, animals that received GPDTM antigen followed formed. Results are shown in Table 5. Three different
immune sera were used for transfer. Group 1 was givenby challenge with the MBGV (strain Musoke) had a higher
survival rate than those challenged with MBGV (strain convalescent pooled sera obtained 28 days after infec-
tion of strain 13 guinea pigs that had been infected withRavn). In the Hartley groups that were immunized with
GPDTM and challenged with MBGV (strain Musoke) a guinea pig avirulent plaque-purified derivative of MBGV
(strain Musoke). Group 2 animals were given a serum(groups 9 and 11), 4/5 animals survived in each group.
Interestingly, the animal that died in group 9 did not have pool from strain 13 guinea pigs that had been immunized
three times with MBGV (strain Musoke) virion and subse-a detectable viremia on day 7, but time to death was not
substantially delayed. In contrast the animal in group 11 quently survived challenge with MBGV (strain Musoke)
(group 5, day 28 serum, Table 3). Animals in groups 4that died had a high viremia on day 7. Animals in group
11 demonstrated a rise in antibody titer to both homolo- through 7 received dilutions of a serum pool from strain
13 guinea pigs that had been immunized three times withgous and heterologous antigen when pre- and postchal-
lenge sera were compared, while those in group 9 did MBGV (strain Ravn) and subsequently survived challenge
with MBGV (strain Ravn) (group 8, day 28 serum, Tablenot. The strain 13 guinea pigs immunized with GPDTM
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TABLE 4
Results of MBGV Challenge of Strain 13 and Hartley Guinea Pigs Vaccinated with Either Sf9 or Tricoplusia ni-Produced GPDTM
Log10GMT ELISA Titer { SD
Log10
Musoke antigen Ravn antigen PFU/ml
Challenge viremia
Groupa Antigen Day 0 Day 03 Day 33 Day -3 Day 33 GMT { SD MDD { SD S/T
9 (H) Tni GPDTM MBGV strain 4.4 { 0.3 4.1 { 0.3 3.5 { 0.3 3.3 { 0.3 1.7 12† 4/5
Musoke
10 (H) Tni GPDTM MBGV strain 3.9 { 0.2 5.0 { 0.3 2.7 { 0.3 4.8 { 0.1 5.3† 8† 2/3
Ravn
11 (H) Sf9 GPDTM MBGV strain 4.1 { 0.2 5.2 { 0.6 3.3 { 0.3 4.4 { 0.4 4.5† 9† 4/5
Musoke
12 (H) Sf9 GPDTM MBGV strain 4.1 { 0.1 — 3.5 { 0.5 — 4.2 { 1.6 10 { 3.0 0/3
Ravn
13 (H) Adjuvant MBGV strain 2.0 — 2.0 — 5.9 { 0.5 9 { 1.0 0/5
Musoke
14 (H) Adjuvant MBGV strain 2.0 — 2.0 — 5.4 { 0.9 9 { 1.0 0/3
Ravn
15 (13) Tni GPDTM MBGV strain 4.8 { 0.2 4.2 { 0.1 3.5 { 0.1 2.9 { 0.2 1.7 — 5/5
Musoke
16 (13) Tni GPDTM MBGV strain 4.6 { 0.4 5.0 { 0.0 3.2 { 0.2 4.8 { 0.5 6.2† 8† 2/3
Ravn
17 (13) Sf9 GPDTM MBGV strain 4.6 { 0.2 4.3 { 0.5 3.2 { 0.2 2.9 { 0.2 1.7 — 5/5
Musoke
18 (13) Sf9 GPDTM MBGV strain 4.8 { 0.2 5.0 { 0.4 3.3 { 0.3 4.0 { 1.8 1.7 18† 2/3
Ravn
19 (13) PBS MBGV strain 2.0 — 2.0 — 5.3 { 0.2 11 { 2.0 0/3
Musoke
20 (13) PBS MBGV strain 2.0 — 2.0 — 5.6 { 0.3 10 { 1.0 0/5
Ravn
Note. Tni, Trichoplusia ni-produced antigen. †Represents data from the animal(s) that died.
a (H) Represents groups of Hartley guinea pigs; (13) represents groups of Strain 13 guinea pigs.
3). Animals in groups 3 and 8 were given HBSS as a obtained when serum from MBGV (strain Ravn) immune
animals was transferred to naive animals, followed bycontrol. All animals in groups 1 and 2 survived challenge,
indicating no substantial difference in the quality of anti- challenge with MBGV (strain Ravn) (group 4). Decreasing
the amount of immune serum resulted in a decrease inbody, whether evoked by sublethal infection or by killed
virion in adjuvant. Not surprisingly, the same results were efficacy: animals that received either 3 or 1 ml of serum
TABLE 5




Group Gpig antiserum (ml/Gpig) Challenge (day 0) (day 10) S/T MDD { SD
1 Mus Convalescent 3.0 MBGV strain Musoke 1.7 5/5 —
2 Mus Virion Immunized 3.0 MBGV strain Musoke 1.7 4/4 —
3 HBSS control 3.0 MBGV strain Musoke 4.8 { 0.2 1/5 11.5 { 0.6
4 Ravn Virion Immunized 3.0 MBGV strain Ravn 1.7 3/3 —
5 Ravn Virion Immunized 1.0 MBGV strain Ravn 1.7 3/3 —
6 Ravn Virion Immunized 0.3 MBGV strain Ravn 4.6† 1/3 13 { 0.0
7 Ravn Virion Immunized 0.1 MBGV strain Ravn 3.9 { 0.6 0/3 13 { 0.0
8 HBSS control 3.0 MBGV strain Ravn — 0/3 9.3 { 0.6
Note. All samples were adjusted to 3.0 ml total volume with sterile saline to control for any volume effects. †Represents data from the animal(s)
that died.
a Volume represents the amount of serum administered to each animal.
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were completely protected, with no viremias detected on thus presumably trafficed from the endoplasmic reticu-
lum through the Golgi network. Surprisingly a weak reac-day 10 (groups 4 and 5). Thus, any transferred serum
amount of about 3.0 ml/kg (as calculated for group 5) or tion with MAA was also observed, indicating the pres-
ence of small amounts of sialic acid residues on thegreater was fully effective. Of guinea pigs that received
0.3 ml immune serum, 1/3 survived (group 6). The two protein. Although insect cells are thought either not to
add sialic acid to glycoproteins or to trim off added sialicguinea pigs that died had high viremias on day 10, but
died 3–4 days later than control animals. The guinea acid residues (Kretzchmar et al., 1994; Jarvis and Finn,
1995), there are some reports indicating that insect cellspig that survived had no detectable viremia on day 10.
Suggesting a rather precise therapeutic cutoff in this ex- may indeed add sialic acid to some proteins (Davis and
Wood, 1995). Although the reaction of GP with MAA wasperiment, the surviving animal in group 6 was smaller
than the other two and thus received 1.5 ml serum/kg, weak, it was reproducible. In interpreting the importance
of differences in glycosylation between Sf9 and Veroas compared to the unprotected animals which received
about 0.5 ml/kg. Animals that received only 0.1 ml of cells, it should be noted that differences in GP lectin-
binding patterns were also observed when MBGV wasantiserum all succumbed to infection with high viremia
on day 10, but with a time of death delayed by 3–4 days grown in a variety of mammalian cell types (Feldmann
et al., 1994).compared to control animals. Within the limits of this
study, we did not observe any adverse effects of antibod- Further characterization of the recombinant proteins
using Mabs directed against MBGV (strain Musoke) GPies, such as increased viremias or accelerated disease.
indicated that the GPDTM was secreted into the serum-
free supernatant of recombinant baculovirus-infectedDISCUSSION
cells and contained several epitopes found in virion-as-
sociated GP. Sixteen of 17 MBGV GP-specific Mabs ex-To determine some of the requirements of a safe and
effective vaccine against MBGV, we initiated studies to amined reacted equally well with GPDTM and MBGV
(strain Musoke). The difference in reactivity of III-5B8 withidentify protective antigens present in the virion. The gly-
coprotein gene of MBGV (strain Musoke) was success- MBGV (strain Musoke) and GPDTM may be due to an
altered epitope or different glycosylation in GPDTM thatfully cloned into a recombinant baculovirus vector and
expressed in insect cells. In addition to GP, a truncated, resulted in less efficient binding of this Mab. In addition,
only two of the MBGV (strain Musoke) GP-specific Mabssecreted form of MBGV GP was produced. The GP and
GPDTM products were specifically recognized by anti- examined reacted well with MBGV (strain Ravn) GP. The
lack of reactivity of MBGV (strain Musoke) anti-GP MabsMBGV sera when immunoprecipitated from infected in-
sect cell lysate, suggesting these products retained at with MBGV (strain Ravn) was most likely due to the heter-
ogeneity of GP in these two (strains of MBGV) and ex-least some of the authentic epitopes present in virion
proteins. The faster migration of recombinant GP com- plains the incomplete cross-protection observed in ani-
mals immunized with GPDTM and challenged withpared to authentic GP in SDS–PAGE has been exten-
sively evaluated elsewhere (Becker et al., 1996) and was MBGV-strain Ravn. Because the recombinant antigen re-
acted so well in ELISA with Mabs, and the relative easemost likely due to differential glycosylation in insect and
mammalian cells. Interestingly, the recombinant GPDTM with which large quantities can be made, there is poten-
tial for use of this antigen as a diagnostic reagent. Toproduct in supernatant has an apparent molecular mass
that is less than virion GP but greater than either the investigate this possibility further, the GPDTM antigen
was compared to purified MBGV as an ELISA antigen onfull-length recombinant GP product or GPDTM from cell
lysates. a titration of convalescent guinea pig serum. The results
demonstrated that the GPDTM was a useful tool in distin-Characterization of the expressed proteins by lectin
blots and ELISA demonstrated that the recombinant pro- guishing anti-GP response from responses to other virion
proteins.teins differed in carbohydrate content compared to virion-
associated GP, but retained their antigenicity with re- Using the guinea pig model, the efficacy of both a
prototypical killed virus vaccine and the recombinantspect to several GP-specific Mabs. The glycosylation pat-
terns of the Sf 9-produced proteins was not substantially GPDTM protein were examined. Gradient-purified, irradi-
ated virus was able to completely protect strain 13 guineadifferent from those reported by Becker et al. (1996).
Strong reactivity with GNA and weak reactivity with DSA pigs from challenge with either MBGV (strain Musoke) or
MBGV (strain Ravn). While protection of the recombinantindicated that the product immunoprecipitated from GP-
producing Sf 9 cell lysates was composed of two forms GPDTM-immunized animals was achieved against MBGV
(strain Musoke), protection was more difficult to achieve inof the protein. The majority of the protein contained un-
processed, high mannose-type glycans, while a minority animals challenged with MBGV (strain Ravn). This lack of
cross-protection may have been due to either a differenceof the protein contained processed, complex N-linked
glycans. In addition, the reactivity with PNA indicates that in the quantity or quality of antibody produced by animals
immunized with GPDTM compared to those immunizedat least of some of the protein was O-glycosylated and
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with virion. Since GPDTM was cloned from MBGV (strain in protection cannot be excluded, as the presentation of
the antigen may play a key role in developing effectiveMusoke) and the MBGV (strain Musoke) and MBGV (strain
Ravn) GP proteins differ by 22% in amino acid sequence, immunity. Specifically, the induction of a cytotoxic T-cell
response by these antigens may be required for effectivethe deficiency of cross-protection observed was not wholly
unexpected. Animals immunized with GPDTM may contain protection. Further studies of the protective efficacies of
NP- and VP-40 using methods of immunization that favorantibodies that neutralize MBGV (strain Musoke) well, but
not MBGV (strain Ravn). Attempts were made to measure a T-cell response may prove more fruitful.
Historically, the prospects for an effective vaccineneutralizing antibodies in the guinea pig sera using a
plaque-reduction neutralization test to address this ques- against filovirus infection was questionable at best. Here
we were able to demonstrate, in a guinea pig modeltion; however, titers were low and no correlation between
protection and presence of neutralizing antibody was ob- system, that the glycoprotein gene product can serve
as a protective immunogen for MBGV. While antigenicserved. Because of the difficulty in quantitating MBGV neu-
tralizing antibody levels in serum, the absence of correlation variation of MBGV makes a monovalent vaccine problem-
atic, complete protection against two types of MBGV wasobserved may be the result of insufficient sensitivity of this
assay for filoviruses. In addition, the virion-immunized ani- obtained using killed virus as an immunogen. Further
work is required to determine what the determinants ofmals developed antibodies not only against GP but also
against the other major virion proteins, while the GPDTM- cross-protection are. These may include antibody to
other viral proteins or cell-mediated immunity directedimmunized animals only produced antibodies directed
against GP. Since the GP protein is expected to be the against one or more of the viral proteins. In addition, the
effectiveness of a subunit vaccine in nonhuman primatesmost variable of the virion proteins, it remains possible that
immune responses to other virion proteins, which are more must be evaluated. Results in nonhuman primates have
shown that passive protection from Ebola infection isconserved, may result in more efficient cross-protection. A
third possibility is that the amount of antibody produced easier to achieve in guinea pigs than in primates (Jahrling
et al., 1996). Thus, the promise of any vaccination strat-in GPDTM-immunized animals was insufficient for cross-
protection. This dose effect may be responsible for the egy for filoviruses should be viewed with caution until
protection is also demonstrated in nonhuman primates.observation in the second protection experiment where
strain 13 and Hartley guinea pigs were immunized with
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